Publications by authors named "Jennifer L F Lee"
Article Synopsis
- - SARS-CoV-2 is still a major cause of death in North America, and this study examines how methotrexate and tumor necrosis factor inhibitors (TNFi) affect vaccine responses in patients with immune-mediated inflammatory diseases (IMID).
- - Researchers collected and analyzed serum samples from 479 adults with conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) across Canada to evaluate neutralization responses to COVID-19 vaccination.
- - The results indicated that both methotrexate and TNFi independently reduced the ability to neutralize the virus, underscoring the need for careful vaccination strategies as COVID-19 remains widespread.
Objective: In the face of the ongoing circulation of SARS-CoV-2, the durability of neutralization post-COVID-19 vaccination in immune-mediated inflammatory disease (IMID) is a key issue, as are the effects of medications.
Methods: Adults (n = 112) with inflammatory bowel disease, psoriasis/psoriatic arthritis, rheumatoid arthritis, spondylarthritis, and systemic lupus were recruited from participating Canadian medical centers from 2021 to 2023. We focused on log-transformed neutralization (lentivirus methods) as a continuous outcome, with separate models for wild-type and Omicron strains BA.
Objective: To determine how serologic responses to coronavirus disease 2019 (COVID-19) vaccination and infection in immune-mediated inflammatory disease (IMID) are affected by time since last vaccination and other factors.
Methods: Post-COVID-19 vaccination, data, and dried blood spots or sera were collected from adults with rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis and spondylarthritis, and psoriasis and psoriatic arthritis. The first sample was collected at enrollment, then at 2 to 4 weeks and 3, 6, and 12 months after the latest vaccine dose.
Objective: To determine cancer incidence in a large clinical juvenile-onset arthritis population.
Methods: We combined data from 6 existing North American juvenile-onset arthritis cohorts. Patients with juvenile-onset arthritis were linked to regional cancer registries to detect incident cancers after cohort entry, defined as first date seen in the paediatric rheumatology clinic.